Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Fluorodeoxyglucose F18 2tivozanib 1tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1regorafenib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1Quality of Life 1Patient Reported Outcome Measures 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lactones 1Irinotecan 1Interleukin-2 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × tivozanib × NET × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡